Themis Medicare (Small Cap - Next Multibagger) Share Target 2024, 2025 To 2039
|
Themis Medicare Limited |
|||
|
Price: ₹268.65 | ||
| 52 Week Low: ₹168.55 52 Week High: ₹317.00 |
|||
| Market Capital: 1,962.75 Crore (Smallcap) | |||
| Healthcare -> Drug Manufacturers—Specialty & Generic | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Themis Medicare Share Price Target For 2024
- 1.1.1: Themis Medicare Share Price Target Table For 2024
- 1.1.2: Short-Term Technical Outlook
- 1.2: Themis Medicare Share Price Target For 2025
- 1.2.1: Themis Medicare Share Price Target Table For 2025
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Themis Medicare Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
- 3: Themis Medicare Brief Company Overview
- 4: Themis Medicare Financial Performance
- 4.0.1: Is Themis Medicare A Good Buy For Long Term?
To predict the Themis Medicare's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Themis Medicare Share Price Target For 2024
The line chart displays the monthly closing prices of Themis Medicare with a black line. The green line shows three potential target prices for 2024, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Themis Medicare shares in 2024, see the table below.
Themis Medicare Share Price Target Table For 2024
| Level | Value | Analysis |
|---|---|---|
| 2024 Target 3 | 281.0 (+4.59%) | Price Action: 22 Nov 2024 Low |
| 2024 Target 2 | 278.04 (+3.49%) | Technical Indicator: MA50 |
| 2024 Target 1 | 274.9 (+2.32%) | Price Action: 19 Dec 2024 High |
| Current Price | 268.65 | Themis Medicare's share price as of 20 Dec 2024 |
| Stop Loss 1 | 265.6 (-1.14%) | Price Action: 01 Nov 2024 High |
| Stop Loss 2 | 262.25 (-2.39%) | Price Action: 05 Nov 2024 Low |
| Stop Loss 3 | 258.83 (-3.66%) | Price Action: Mar 2024 High |
Short-Term Technical Outlook
Current Technical Position: Themis Medicare is displaying bearish momentum trading below key moving averages.
Key Technical Level: The 50-day moving average at ₹278 serves as the nearest technical reference point.
Historical Returns: 3-month: -1.67% | 6-month: +28.40% | 1-year: +25.99%
Themis Medicare Share Price Target For 2025
The line chart displays the monthly closing prices of Themis Medicare with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Themis Medicare shares in 2025, see the table below.
Themis Medicare Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 375.89 (+39.91%) | Price Action: Chart |
| 2025 Target 2 | 368.88 (+37.30%) | Price Action: Chart |
| 2025 Target 1 | 365.23 (+35.95%) | Fibonacci Extension Level 64.90% |
| Current Price | 268.65 | Themis Medicare's share price as of 20 Dec 2024 |
| Stop Loss 1 | 242.71 (-9.66%) | Price Action: Jan 2024 High |
| Stop Loss 2 | 239.37 (-10.90%) | Technical Indicator: MA250 |
| Stop Loss 3 | 235.23 (-12.44%) | Price Action: Apr 2024 High |
Long-Term Technical Outlook
52-Week Range Analysis: Themis Medicare is currently trading at 67.4% of its 52-week range (₹168.55 - ₹317).
Long-Term Trend Analysis: The stock is maintaining a bullish long-term trend, trading above both 150-day and 250-day moving averages.
Long-Term Performance: 1-year: +25.99% | 3-year: +187.97% | 5-year: +764.38%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Themis Medicare Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹268.65 | ||
| 2024 | ₹315.47 | +17.43% | ₹320.20 |
| 2025 | ₹416.29 | +31.96% | ₹422.53 |
| 2026 | ₹507.45 | +21.90% | ₹515.06 |
| 2027 | ₹641.05 | +26.33% | ₹662.15 |
| 2028 | ₹813.73 | +26.94% | ₹825.94 |
| 2029 | ₹897.41 | +10.28% | ₹910.87 |
| 2030 | ₹977.24 | +8.90% | ₹991.90 |
| 2031 | ₹1,046.08 | +7.04% | ₹1,061.77 |
| 2032 | ₹1,202.33 | +14.94% | ₹1,268.46 |
| 2033 | ₹1,420.03 | +18.11% | ₹1,441.33 |
| 2034 | ₹1,479.34 | +4.18% | ₹1,501.53 |
| 2035 | ₹1,538.20 | +3.98% | ₹1,573.76 |
| 2036 | ₹1,584.71 | +3.02% | ₹1,727.52 |
| 2037 | ₹1,763.62 | +11.29% | ₹1,881.28 |
| 2038 | ₹2,026.34 | +14.90% | ₹2,056.74 |
| 2039 | ₹1,994.45 | -1.57% | ₹2,024.37 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Themis Medicare Brief Company Overview
Themis Medicare: A Pharmaceutical Powerhouse Established in 1952, Themis Medicare is a leading pharmaceutical company based in Mumbai, India. With a global presence, Themis Medicare manufactures and markets a wide range of pharmaceutical products. Key Products and...
Services: Active Pharmaceutical Ingredients (APIs) Formulations for various therapeutic areas Generic and branded medicines Diverse Product Portfolio: Themis Medicare's diverse product range covers a variety of therapeutic areas, including: Anti-tuberculosis Anti-malarials Cardiology Pain management Anti-infectives Industry Reputation: Themis Medicare has a strong reputation in the pharmaceutical industry, known for its quality products and commitment to healthcare.Themis Medicare Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 1,962.75 Crore | Market valuation of Themis Medicare's shares. |
| Revenue (TTM) | 364.04 Crore | Total revenue generated by Themis Medicare over the past twelve months. |
| Net Income (TTM) | +452,856,000.00 | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +6.01% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +12.43% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
-7.10% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) |
-44.70% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio |
25.97 | Company's total debt divided by total shareholder equity. |
| Total Debt | 94.58 Crore | Sum of Themis Medicare's current & long-term financial obligations. |
| Total Cash | 22.38 Crore | Total amount of liquid funds available to Themis Medicare. |
| Beta | 0.6 | Beta is less than 1 indicating that the Themis Medicare's price is less volatile than the market. |
Is Themis Medicare A Good Buy For Long Term?
Themis Medicare, a small-cap stock with a market cap of Rs. 1,962.75 Crore, has shown mixed performance recently. Despite a 12.43% profit margin, it has a concerning -44.7% change in earnings and -7.1% change in revenue. While it has generated strong returns over the past 3, 5, and 12 months, it has a high debt of Rs. 94.58 Crore. Given these factors, it may be considered as an average buy for long-term investment, but investors should proceed with caution and monitor the company's financial performance closely.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
